Vascular

Markets for this technology for vascular opportunities are multiple. The product can be used for general vascular replacements in the periphery, and in kidney failure patients who require graft placement for dialysis machine access. Patients could benefit tremendously from Humacyte's technology, which could be limb-saving or life-saving. Patients requiring chronic dialysis commonly require repeated arterial graft operations during their lifetimes, because current graft technology does not perform over extended periods of time. The broadest potential market for Humacyte's technology is the coronary artery bypass (CABG) market. CABG patients who currently must undergo harvest of saphenous vein or mammary artery to provide bypass vessels could forego these risky procedures, if an alternative arterial graft was readily available. Humacyte's technology would decrease complications, shorten operating time and hospital stay, and thereby decrease costs as well as patient morbidity. The most easily penetrated segment of this market would be those patients requiring bypass but possessing no suitable vein or artery of their own. In the US alone, 100,000 patients do not undergo needed CABG surgery because of lack of conduit. Since these patients have no other effective treatment option, Humacyte's product will be well suited to treat them.

Humacyte's human cell-derived acellular matrices have significant competitive advantages over currently marketed products:

Completely human cell-derived from well-characterized cell source - no risk of transmission of animal-borne infectious agents (e.g., BSE)

Completely biological leading to better host acceptance and efficacy

Non-immunogenic - off the shelf

Robust mechanical strength

Suturable and leakproof in vivo

Integrates rapidly with native surrounding tissue - without abnormal tissue growth

May be stored long-term

May be seeded with autologous endothelial cells for small caliber vascular applications

May be impregnated with drugs or biologics to allow local and controlled release

May be combined with existing membrane products to improve or augment performance features

http://www.humacyte.com/pages/products/vascular.html